Toggle Main Menu Toggle Search

Open Access padlockePrints

Metagenomics shows low-energy anaerobic-aerobic treatment reactors reduce antibiotic resistance gene dissemination from domestic wastewater

Lookup NU author(s): Dr Beate Christgen, Professor David GrahamORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Effective domestic wastewater treatment is among our primary defences against the dissemination of infectious waterborne disease. However, reducing the amount of energy used in treatment processes has become essential for the future. One low-energy treatment option is anaerobic-aerobic sequence (AAS) bioreactors, which use an anaerobic pre-treatment step (e.g., anaerobic hybrid reactors) to reduce carbon levels followed by some form of aerobic treatment. Although AAS is common in warm climates, it is not known how its compares with other treatment options relative to disease transmission, including its influence on antibiotic resistance (AR) in treated effluents. Here we used metagenomic approaches to contrast the fate of AR genes (ARG) in anaerobic, aerobic and AAS bioreactors treating domestic wastewater. Five reactor configurations were monitored for six months, and treatment performance, energy use and ARG abundance and diversity were compared in influents and effluents. AAS and aerobic reactors were superior to anaerobic units in reducing ARG-like sequence abundances, with effluent ARG levels of 29, 34 and 74 ppm (198 ppm influent), respectively. AAS and aerobic systems especially reduced aminoglycoside, tetracycline, and β-lactam ARG levels relative to anaerobic units, although 63 persistent ARG subtypes were detected in effluents from all systems (of 234 assessed). Sulfonamide and chloramphenicol ARG levels were largely unaffected by treatment, whereas a broad shift from target-specific ARGs to ARGs associated with multidrug-resistance was seen across influents and effluents. AAS reactors show promise for future applications because they can reduce more ARGs for less energy (32% less energy here), but all three treatment options have limitations and need further study.


Publication metadata

Author(s): Christgen B, Yang Y, Ahammad SZ, Li B, Rodriquez DC, Zhang T, Graham DW

Publication type: Article

Publication status: Published

Journal: Environmental Science & Technology

Year: 2015

Volume: 49

Issue: 4

Pages: 2577-2584

Print publication date: 17/02/2015

Online publication date: 20/01/2015

Acceptance date: 20/01/2015

Date deposited: 21/01/2015

ISSN (print): 0013-936X

ISSN (electronic): 1520-5851

Publisher: American Chemical Society

URL: http://dx.doi.org/10.1021/es505521w

DOI: 10.1021/es505521w


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
AstraZeneca-UK
EP/K004689/1Engineering and Physical Science Research Council (EPSRC)
EP/F008473/1Engineering and Physical Science Research Council (EPSRC)

Share